Literature DB >> 33746449

What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease?

Deepu David1, Chundamannil E Eapen2.   

Abstract

Of the currently available drugs tested to treat nonalcoholic fatty liver disease (NAFLD), the most efficacious drugs are pioglitazone (an insulin sensitizer) and vitamin E (an antioxidant). By targeting insulin resistance, the key pathogenic mechanism underlying metabolic syndrome and NAFLD, pioglitazone maybe the preferred drug to treat NAFLD. As we await the results of research trials into multiple new drugs to treat NAFLD, when should we use the currently available patients to treat NAFLD at the present time? To date, no drug has been approved by regulatory agency specifically to treat NAFLD. However, many drugs have been approved to treat other components of metabolic syndrome such as diabetes mellitus and dyslipidemia. Are we underutilizing the currently available drugs to treat NAFLD? Herein, we review the benefits and concerns of the use of these currently available drugs to treat NAFLD and suggest clinical scenarios, wherein the clinician should consider using these drugs.
© 2020 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  NAFLD; NASH; nonalcoholic fatty liver disease; treatment of NAFLD

Year:  2020        PMID: 33746449      PMCID: PMC7953000          DOI: 10.1016/j.jceh.2020.09.001

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  55 in total

1.  The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial.

Authors:  William W Shields; K E Thompson; G A Grice; S A Harrison; W J Coyle
Journal:  Therap Adv Gastroenterol       Date:  2009-05       Impact factor: 4.409

2.  Risk of development of hepatocellular carcinoma in patients with NASH-related cirrhosis.

Authors:  D N Amarapurkar; M Dharod; Sonali Gautam; N Patel
Journal:  Trop Gastroenterol       Date:  2013 Jul-Sep

3.  Parental determinants of metabolic syndrome among adolescent Asian Indians: A cross-sectional analysis of parent-offspring trios.

Authors:  Rahul Baxi; Senthil K Vasan; Samuel Hansdak; Prasanna Samuel; Visali Jeyaseelan; Finney S Geethanjali; Ruth R Murray; Padmanaban Venkatesan; Nihal Thomas
Journal:  J Diabetes       Date:  2015-07-21       Impact factor: 4.006

4.  Can Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease Co-Exist?

Authors:  Manu Mehta; Sandeep Satsangi; Ajay Duseja; Sunil Taneja; Radha K Dhiman; Yogesh Chawla
Journal:  J Clin Exp Hepatol       Date:  2017-02-03

5.  Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J).

Authors:  Yuichiro Eguchi; Yoichiro Kitajima; Hideyuki Hyogo; Hirokazu Takahashi; Motoyasu Kojima; Masafumi Ono; Norimasa Araki; Kenichi Tanaka; Miyuki Yamaguchi; Yayoi Matsuda; Yasushi Ide; Taiga Otsuka; Iwata Ozaki; Naofumi Ono; Takahisa Eguchi; Keizo Anzai
Journal:  Hepatol Res       Date:  2014-05-28       Impact factor: 4.288

6.  Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality.

Authors:  Edgar R Miller; Roberto Pastor-Barriuso; Darshan Dalal; Rudolph A Riemersma; Lawrence J Appel; Eliseo Guallar
Journal:  Ann Intern Med       Date:  2004-11-10       Impact factor: 25.391

7.  Lean NASH: distinctiveness and clinical implication.

Authors:  Kausik Das; Abhijit Chowdhury
Journal:  Hepatol Int       Date:  2013-10-17       Impact factor: 6.047

8.  Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.

Authors:  Jean-François Dufour; Carl M Oneta; Jean-Jacques Gonvers; Florian Bihl; Andreas Cerny; Jean-Michel Cereda; Jean-Franco Zala; Beat Helbling; Michael Steuerwald; Arthur Zimmermann
Journal:  Clin Gastroenterol Hepatol       Date:  2006-12       Impact factor: 11.382

9.  Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.

Authors:  Lee-Lee Lai; Shireene Ratna Vethakkan; Nik Raihan Nik Mustapha; Sanjiv Mahadeva; Wah-Kheong Chan
Journal:  Dig Dis Sci       Date:  2019-01-25       Impact factor: 3.199

10.  Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease.

Authors:  Fabio Nascimbeni; Judith Aron-Wisnewsky; Raluca Pais; Joan Tordjman; Christine Poitou; Frederic Charlotte; Pierre Bedossa; Thierry Poynard; Karine Clément; Vlad Ratziu
Journal:  BMJ Open Gastroenterol       Date:  2016-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.